Sales & Marketing

Patients to be selected for treatment based on approved companion diagnostic.

Collaboration aims to educate and provide funding for malnutrition programs.

Alliance aims to expand access to innovative healthcare solutions.

Bloomberg Intelligence survey credits increased medication access for potential spike.

Partnership to focus on drug discovery platform.

Inpefa to support multiple cardiovascular issues.

Krystal Biotech treatment to support patients with dystrophic epidermolysis bullosa.

Purchase leaves biotech’s remaining assets on the table.

Advertising pause aims to prevent stimulating further demand, company says.

Treatment supported under agency’s accelerated approval program.

Marks seventh approval for Rinvoq in the pharmaceutical field.

Miebo reported as the first cleared remedy that directly targets tear evaporation.

Biotech company to receive $55 million upfront, per terms of the deal.

Nelarabine injection to be first Shorla product approved in the US.

With drugs taking longer to hit the market, will biopharma’s approval count be affected?

Winselow Tucker, chief commercial officer, Loxo@Lilly (Eli Lilly’s oncology unit), discusses where to make budget cuts, how to motivate a team, what he wishes he had known earlier in his career, as well as his new role at Loxo@Lilly.

Rexulti to be first authorized treatment for agitation associated with dementia.

Collaboration expected to drive consumer and patient engagement in the region.

Government sponsored study to test effectiveness of Quviviq in those living with PTSD.

By using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.

Fran Pollaro chats with Matt Titus about successfully navigating in crowded therapeutic markets with tailored messaging and data-driven strategies.

Explore the changing dynamics of healthcare professionals' communication preferences in a post-pandemic world, as Pharm Exec's Fran Pollaro has a no frills discussion about InCrowd's latest insights with chief customer officer Caleb Costa.

Lumryz set to become first approved bedtime oxybate for those living with disease.

Acquisition expected to support pharmaceutical’s blindness regeneration campaign.

Kyowa Kirin now leads the commercial efforts for Crysvita in 40 countries, continuing its commitment to address the needs of people living with rare diseases.

Biogen Inc. announced the approval, a groundbreaking treatment for adults with ALS, offering hope to patients suffering from SOD1-ALS, a rare and fatal genetic form of the disease.

Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with recurrent C. difficile infections.

First once-every-two-months long-acting injectable offers sustained therapeutic concentrations for patients.

Industry leaders threaten to devote resources elsewhere.

Christopher Boerner, chief commercialization officer, set to succeed Caforio in November.